Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Contracted reimbursement now includes molecular profiling alongside tumor cell enumeration, adding approximately 6 million covered lives.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cerenome (CNSY) secured an in-network agreement through its CNSide Diagnostics subsidiary with Florida Blue, effective October 1, 2026. The agreement establishes contracted reimbursement for CNSide cerebrospinal fluid (CSF) tumor cell enumeration and molecular profile tests for solid tumors and blood cancers involving the central nervous system. It is CNSide’s first payer agreement covering both tumor cell enumeration and molecular profiling.
The agreement adds approximately 6 million covered lives, bringing CNSide’s contracted payer footprint to approximately 164 million commercial and Medicare Advantage covered lives. The CSF Molecular Profile tests are now commercially available.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointFlorida Blue agreement establishes contracted reimbursement for tumor cell enumeration and molecular profiling, effective October 1, 2026.
- Minor pointFlorida Blue adds approximately 6 million covered lives to CNSide’s contracted payer footprint.
Negative
- None.
Key Figures
- Additional covered lives
- Approximately 6 million covered lives
- Added by the Florida Blue agreement
- Total contracted covered lives
- Approximately 164 million covered lives
- Commercial and Medicare Advantage agreements
- Agreement effective date
- October 1, 2026
- Florida Blue in-network ancillary provider agreement
Historical Context
-
Announced molecular-profile test launch for October 12, extending CNSide beyond tumor-cell enumeration.
-
Michigan payer agreement added five million members and brought contracted coverage to 158 million.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cerebrospinal fluid medical
molecular profiling medical
leptomeningeal metastases medical
hematologic malignancies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration
Expands CNSide contracted payer access to approximately 164 million covered lives
HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has entered into an in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida, Inc. (Florida Blue), effective October 1, 2026.
The agreement establishes contracted reimbursement for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test as well as CNSide® CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. It is the first CNSide payer agreement to include both tumor cell enumeration and molecular profiling.
The Florida Blue agreement adds approximately 6 million covered lives to CNSide’s contracted payer footprint. Combined with previously announced payer agreements, CNSide has now established in-network agreements representing approximately 164 million commercial and Medicare Advantage covered lives, reflecting continued execution of the Company’s national reimbursement strategy.
“This agreement with Florida Blue represents an important milestone in CNSide’s commercial trajectory,” said Marc Hedrick, M.D., Cerenome’s President and Chief Executive Officer. “By expanding contracted reimbursement to both cellular and molecular CSF testing, we are advancing CNSide as a broader CSF diagnostics platform for CNS oncology, combining tumor-cell analysis and molecular profiling to better characterize and monitor cancers involving the central nervous system.”
The Florida Blue agreement expands the scope of CNSide’s contracted reimbursement beyond tumor cell detection in leptomeningeal metastases to include molecular profiling of CNS malignancies. CNSide® CSF Molecular Profile - Solid Tumor provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed primary CNS tumors or solid tumors metastatic to the CNS, including brain and leptomeningeal metastases. CNSide® CSF Molecular Profile - Hematologic Malignancy provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed hematologic malignancies involving the CNS. CNSide® CSF Molecular Profile tests are now commercially available through CNSide.
The DNA and RNA CSF molecular profiling approach underlying CNSide® CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study of 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS, published in The Journal of Liquid Biopsy.
The clinical utility of CNSide CSF tumor cell analysis in leptomeningeal metastases is supported by evaluation in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. Since 2020, more than 11,000 CNSide® tests have been performed at more than 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide.
About Florida Blue
Driven by its mission of helping people and communities achieve better health, Florida Blue is the leading health insurer in Florida, and part of GuideWell, a not-for-profit health solutions company. Florida Blue offers a range of health plans and personalized care programs for individuals, families, businesses of all sizes, and Medicare beneficiaries. For over 80 years, the organization has been member centric and committed to making health care as accessible and affordable as possible. Serving more than six million members across all 67 Florida counties, Florida Blue has more than 7,000 employees, is headquartered in Jacksonville, Fla., is owned by its policyholders, and is an independent licensee of the Blue Cross Blue Shield Association.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes cerebrospinal fluid (CSF)-based diagnostic tests for cancers involving the central nervous system. The CNSide® CSF diagnostics platform combines cellular analysis, biomarker characterization, and molecular profiling to support the detection, characterization, and longitudinal assessment of CNS malignancies. CNSide currently offers CNSide® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases and plans to launch CNSide® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS in October 2026. For more information, visit https://www.cnside-dx.com
About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
Investor Contact
CORE IR
IR@cerenome.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What tests does Cerenome’s Florida Blue agreement cover?
The agreement covers CNSide CSF Tumor Cell Enumeration and CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. It is CNSide’s first payer agreement to include both tumor cell enumeration and molecular profiling.
How many covered lives does CNSide’s payer network represent after the Florida Blue agreement?
CNSide’s in-network agreements now represent approximately 164 million commercial and Medicare Advantage covered lives. The Florida Blue agreement adds approximately 6 million covered lives to that contracted payer footprint.